Clinical trials
Limited Stage Small Cell Lung Cancer clinical trials
Below are recruiting limited stage small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 460 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06931717RecruitingPhase 3
Immunotherapy after lung cancer surgery for those not getting chemo
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
ViennaAges 18 years+ - NCT06931626RecruitingPhase 1
Study of NMS-03305293 for relapsed small cell lung cancer
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
Peoria, IllinoisAges 18 years+ - NCT06930794RecruitingPhase 3
Study of Vebreltinib Plus Chemo for MET-Positive Lung Cancer
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06922539RecruitingPhase 1
Experimental drug ST-001 nanoFenretinide for small cell lung cancer
This phase 1 trial tests an experimental drug called ST-001 nanoFenretinide for people with small cell lung cancer that has returned or not responded to standard chemotherapy. The drug is a newer form of fenretinide, which is related to vitamin A, and may work differently to attack cancer cells.
Los Angeles, CaliforniaAges 18 years+ - NCT06918132RecruitingPhase 2
Cemiplimab and Fianlimab before lung cancer surgery
This trial tests whether two immunotherapy drugs (cemiplimab and fianlimab) given before surgery can help treat stage IB to IIIB non-small cell lung cancer. You must have a PD-L1 level of at least 1% and your surgeon must think the tumor can be fully removed.
Rochester, MinnesotaAges 18 years+ - NCT05623319RecruitingPhase 2
Pembrolizumab plus olaparib for extensive small cell lung cancer
This Phase 2 study tests whether combining pembrolizumab and olaparib can improve outcomes in people with extensive-stage small cell lung cancer. It mainly aims to shrink tumors and help control the cancer for longer.
Meldola, Forlì CesenaAges 18 years+ - NCT06907615RecruitingPhase 2
Study of HLX43 for advanced non-small cell lung cancer
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT06908070RecruitingPhase 4
Chemoradiation, surgery, then durvalumab for stage 3 lung cancer
This trial tests if giving the immunotherapy drug durvalumab after chemoradiation and surgery helps people with stage 3 non-small cell lung cancer. You will receive standard chemoradiation, then have surgery, and then get durvalumab to see if it lowers the chance of the cancer coming back.
AmsterdamAges 18 years+ - NCT06436625Recruiting
Outpatient rehab for lung cancer patients on immunotherapy
This study tests whether a structured outpatient exercise program can help people with non-small cell lung cancer who are already receiving immunotherapy. It is designed for those whose cancer is stable or responding after initial treatment.
ViennaAges 18–120 - NCT06899126RecruitingPhase 3
Study of a drug combo for first-line HER2-positive lung cancer
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
Anchorage, AlaskaAges 18 years+ - NCT05989542RecruitingPhase 3
Study of vebreltinib for MET-mutated lung cancer
This study tests a new targeted pill (vebreltinib) for people with advanced non-small cell lung cancer that has a specific gene change (MET exon 14 mutation). It is for people who have not had much or any prior treatment. The goal is to see if this medicine can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT06868836RecruitingPhase 2
Study of a new antibody combination for advanced lung cancer after targeted therapy
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT06873555RecruitingPhase 1/Phase 2
Study of a new drug for ovarian cancer and other advanced solid tumors
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
Bengbu, AnhuiAges 18 years+ - NCT06865339RecruitingPhase 2
Radiation plus immunotherapy for advanced lung cancer
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
The Bronx, New YorkAges 18 years+ - NCT06848699RecruitingPhase 1/Phase 2
Testing HLX43 plus Serplulimab for advanced solid tumors
This trial tests a new combination of two cancer drugs (HLX43 and Serplulimab) for people with advanced solid tumors, especially those with a specific type of lung cancer (NSCLC) that has an EGFR mutation. The goal is to see if this combination can shrink tumors or slow their growth.
Hunan, ChangshaAges 18–75 - NCT06773507RecruitingPhase 1
Study of BC008-1A for advanced solid tumors
This trial tests a new drug called BC008-1A for people with advanced esophageal cancer or non-small cell lung cancer that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
TianjinAges 18 years+ - NCT06838208RecruitingPhase 2
Immunotherapy plus chemo and radiation for first-line extensive-stage small cell lung cancer
This study tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy followed by targeted chest radiation as the first treatment for extensive-stage small cell lung cancer. The goal is to see if adding radiation after chemo-immunotherapy works better than standard treatment alone.
Hefei, AnhuiAges 18 years+ - NCT06379087RecruitingPhase 2
Radiation, immunotherapy and targeted therapy for early-stage lung cancer
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
Hangzhou, ZhejiangAges 18–75 - NCT05486650Recruiting
Study of focused radiation after PD-1 treatment helped non-lung cancer
This observational study looks at how stereotactic (high-precision) radiation works for advanced non-small cell lung cancer that is stable after PD-1 antibody treatment (sometimes with chemotherapy). It may help doctors better understand which patients benefit from this next treatment step and what side effects to expect.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06816966Enrolling by invitationPhase 2
Chemo-immunotherapy with split radiation for extensive-stage lung cancer
This trial tests a combination of chemotherapy, immunotherapy, and a special type of radiation given in split sessions for people with extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better.
Fuzhou, FujianAges 18 years+ - NCT06617936RecruitingPhase 2
Immunotherapy plus endostatin and chemo for stage III lung cancer
This trial tests a combination of an immunotherapy drug (tislelizumab), an anti-angiogenic drug (endostatin), and standard chemotherapy for people with stage III lung cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
Jinan, ShandongAges 18–75 - NCT06810609RecruitingPhase 2
Immunochemotherapy, surgery, and durvalumab for stage III lung cancer
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
Freiburg im Breisgau, Baden-WurttembergAges 18–74 - NCT06810895Enrolling by invitation
Immunotherapy plus chemo for recurrent cervical cancer
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
WuhanAges 18–75
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for limited stage small cell lung cancer?
- Yes. Clin2 currently lists 460 recruiting limited stage small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a limited stage small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a limited stage small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Small Cell Lung Cancer Extensive Stage
- Non-small Cell Lung Cancer Stage III
- Non Small Cell Lung Cancer
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Stage IIIA Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Squamous Cell Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.